Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) saw its shares make a small gain on Wednesday after the firm announced the exclusive launch of a generic version of Reyataz (atazanavir) capsules in the United States. Even though the gain from this announcement may not be great, it is a step in the right direction for this struggling pharmaceutical giant.
Brendan O’Grady, Executive Vice President, North America Commercial at Teva, commented:
The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection. Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.
Teva has nearly 600 generic medicines available, and it has the largest portfolio of FDA-approved generic products on the market. It holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the United States. Currently, one in seven generic prescriptions dispensed in the country is filled with a Teva generic product.
Reyataz had annual U.S. sales of approximately $402 million, according to IMS data as of October 2017.
While the bump in the share price from this individual announcement is not especially significant, it is still counted as positive momentum for the shares. Year to date the stock is down roughly 48%. However, in just the past month alone the stock is up 38%.
This stock has been under fire for some time, and after shares seemingly bottomed around $11, a recovery seems to be underway.
Shares of Teva were last seen up about 0.4% at $19.00, with a consensus analyst price target of $18.30 and a 52-week range of $10.85 to $38.31.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
